Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The influence of domestic manufacturing capabilities on biologic pricing in emerging economies

An Author Correction to this article was published on 01 November 2019

This article has been updated

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Affordability of biologics across various emerging economies.
Fig. 2: Average drug prices of various classes of biologics from 2007 to 2017 in emerging markets (India, China, Republic of Korea, Nigeria and South Africa).

Change history

  • 01 November 2019

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

References

  1. 1.

    McKinsey. Biosimilars seven years on: where are we and what’s next? https://www.mckinsey.com/~/media/mckinsey/dotcom/client_service/Pharma%20and%20Medical%20Products/PMP%20NEW/PDFs/Biosimilars%20Seven%20years%20on_White%20Paper.ashx (2013).

  2. 2.

    Gross, H. J. & Vietri, F. Barriers to Biologic Therapy Use for Autoimmune Disorders in Emerging Markets, International Society for Pharmacoeconomics and Outcomes Research: 16th Annual European Conference (2013).

  3. 3.

    Ghosh, A., Ray, S., Dewan, S., Shah, K. & Sahani, K. Indian Pharmaceutical Sector (ICRA Ltd., New Delhi, 2012).

    Google Scholar 

  4. 4.

    Pharmaceutical Export Promotion Council of India. 11th Annual Report, 2014–2015 (Government of India, Bangalore, India, 2015).

    Google Scholar 

  5. 5.

    Edney, A. & Mittelman, M. Valeant, Turing would face subpoena vote under Democrat’s plan. Bloomberg http://www.bloomberg.com/news/articles/2015-11-04/valeant-turing-would-face-subpoena-vote-under-democrats-plan (4 November 2015).

  6. 6.

    Kateja, N., Agarwal, H., Hebbi, V. & Rathore, A. S. Biotechnol. Prog. 33, 998–1009 (2017).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Anurag S. Rathore.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rathore, A.S., Shereef, F. The influence of domestic manufacturing capabilities on biologic pricing in emerging economies. Nat Biotechnol 37, 498–501 (2019). https://doi.org/10.1038/s41587-019-0116-0

Download citation

Further reading

Search

Quick links